Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Rockefeller University
Headquarters: New York, NY, United States of America
Website: http://www.rockefeller.edu
Year Founded: 1901
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 6, 2024
Distillery Therapeutics
Targeting cancer cell glycosphingolipid synthesis for antitumor immunity in KRAS-mutant cancers
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 13, 2024
Discovery & Translation
Science Spotlight: Lyell’s scaffold for reenergizing CAR T cells; plus Cirrus, Denali and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 2, 2023
Finance
Aug. 2 Quick Takes: CG Oncology raises $105M crossover round
Plus: Emerson Collective spins out Yosemite with $200M cancer fund, first commercial patient receives Sarepta’s DMD gene therapy, and more
BioCentury | Jul 20, 2023
Management Tracks
Tessier-Lavigne exonerated by review panel, steps down as Stanford president
Plus: Amarin hires Holt to pull off restructuring, turnaround and updates from Accession and Greenleaf
BioCentury | Feb 9, 2023
Management Tracks
Bill Anderson becomes CEO of Bayer
Plus: High leaving AskBio, and updates from Verily, PhRMA, MOMA and more
BioCentury | Aug 9, 2022
Deals
On heels of Parkinson’s readout, Cerevance enters Alzheimer’s discovery deal with Merck
Pharma pays $25M up front to use target discovery platform as privately-held Cerevance plots path forward for wholly-owned clinical program
Items per page:
1 - 10 of 218